Reported reactions are uncommon and usually mild/transient, including: Mild injection-site irritation, redness, or itching Transient headache, light-headedness, or flushing Temporary water retention or joint stiffness (doserelated) Rare mild gastrointestinal discomfort or changes in appetite Rare transient elevation in blood glucose or insulin resistance markers If any severe or persistent symptoms occur (e.g., severe headache with visual changes, severe abdominal pain, or allergic signs), discontinue use and contact your healthcare provider immediately
No, pioglitazone is not a GLP-1
Every resident we support receives tailored attention that helps ensure consistency, balance, and measurable progress
Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry 015/091, January 2022): part 1 with recommendations on Diagnostics and Conservative and Medical Treatment